IBDEI0LR ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10143,2)
 ;;=^5005659
 ;;^UTILITY(U,$J,358.3,10144,0)
 ;;=H35.361^^44^501^20
 ;;^UTILITY(U,$J,358.3,10144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10144,1,3,0)
 ;;=3^Drusen of Macular,Right Eye
 ;;^UTILITY(U,$J,358.3,10144,1,4,0)
 ;;=4^H35.361
 ;;^UTILITY(U,$J,358.3,10144,2)
 ;;=^5005658
 ;;^UTILITY(U,$J,358.3,10145,0)
 ;;=H04.123^^44^501^21
 ;;^UTILITY(U,$J,358.3,10145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10145,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,10145,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,10145,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,10146,0)
 ;;=H35.32^^44^501^28
 ;;^UTILITY(U,$J,358.3,10146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10146,1,3,0)
 ;;=3^Exudative Age-Related Macular Degeneration
 ;;^UTILITY(U,$J,358.3,10146,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,10146,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,10147,0)
 ;;=H35.023^^44^501^29
 ;;^UTILITY(U,$J,358.3,10147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10147,1,3,0)
 ;;=3^Exudative Retinopathy,Bilateral
 ;;^UTILITY(U,$J,358.3,10147,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,10147,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,10148,0)
 ;;=H35.022^^44^501^30
 ;;^UTILITY(U,$J,358.3,10148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10148,1,3,0)
 ;;=3^Exudative Retinopathy,Left Eye
 ;;^UTILITY(U,$J,358.3,10148,1,4,0)
 ;;=4^H35.022
 ;;^UTILITY(U,$J,358.3,10148,2)
 ;;=^5005587
 ;;^UTILITY(U,$J,358.3,10149,0)
 ;;=H35.021^^44^501^31
 ;;^UTILITY(U,$J,358.3,10149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10149,1,3,0)
 ;;=3^Exudative Retinopathy,Right Eye
 ;;^UTILITY(U,$J,358.3,10149,1,4,0)
 ;;=4^H35.021
 ;;^UTILITY(U,$J,358.3,10149,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,10150,0)
 ;;=H40.013^^44^501^32
 ;;^UTILITY(U,$J,358.3,10150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10150,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,10150,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,10150,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,10151,0)
 ;;=H40.012^^44^501^33
 ;;^UTILITY(U,$J,358.3,10151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10151,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,10151,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,10151,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,10152,0)
 ;;=H40.011^^44^501^34
 ;;^UTILITY(U,$J,358.3,10152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10152,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,10152,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,10152,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,10153,0)
 ;;=H52.03^^44^501^41
 ;;^UTILITY(U,$J,358.3,10153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10153,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,10153,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,10153,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,10154,0)
 ;;=H52.02^^44^501^42
 ;;^UTILITY(U,$J,358.3,10154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10154,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,10154,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,10154,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,10155,0)
 ;;=H52.01^^44^501^43
 ;;^UTILITY(U,$J,358.3,10155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10155,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,10155,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,10155,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,10156,0)
 ;;=H59.41^^44^501^44
 ;;^UTILITY(U,$J,358.3,10156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10156,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
